Back to top
more

Cara Therapeutics (CARA)

(Real Time Quote from BATS)

$0.72 USD

0.72
81,246

0.00 (0.62%)

Updated May 13, 2024 12:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (84 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cara (CARA) delivered earnings and revenue surprises of 20.59% and 2.90%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Cara Therapeutics (CARA) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is Cara Therapeutics (CARA) Stock a Solid Choice Right Now?

by Zacks Equity Research

Cara Therapeutics (CARA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Cara Therapeutics (CARA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cara (CARA) delivered earnings and revenue surprises of 1.59% and 67.56%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Cara Therapeutics (CARA) Q1 Earnings Expected to Decline

by Zacks Equity Research

Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cara Therapeutics' Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Cara Therapeutics.

Cara Therapeutics (CARA) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Cara (CARA) delivered earnings and revenue surprises of 1.61% and -19.13%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More

by Zacks Equity Research

Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.

Is the Options Market Predicting a Spike in Cara Therapeutics (CARA) Stock?

by Zacks Equity Research

Investors need to pay close attention to Cara Therapeutics (CARA) stock based on the movements in the options market lately.

    Cara Therapeutics (CARA) Reports Q3 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Cara (CARA) delivered earnings and revenue surprises of -25.42% and 4.01%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

    Analysts Estimate Cara Therapeutics (CARA) to Report a Decline in Earnings: What to Look Out for

    by Zacks Equity Research

    Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Cara (CARA) delivered earnings and revenue surprises of 4.92% and 1.38%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

    Cara Shares Up on Positive Phase III Data for Itchiness Drug

    by Zacks Equity Research

    Cara (CARA) reports positive top-line data from phase III study of Korsuva injection in hemodialysis patients with moderate-to-severe chronic kidney disease-related pruritus.

    Cara Therapeutics (CARA) Reports Q1 Loss, Lags Revenue Estimates

    by Zacks Equity Research

    Cara (CARA) delivered earnings and revenue surprises of -1.82% and -14.70%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

    Implied Volatility Surging for Cara Therapeutics (CARA) Stock Options

    by Zacks Equity Research

    Investors need to pay close attention to Cara Therapeutics (CARA) stock based on the movements in the options market lately.

    Cara Therapeutics (CARA) Reports Q4 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Cara (CARA) delivered earnings and revenue surprises of 11.86% and 65.26%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

    Athersys (ATHX) Q4 Earnings: What's in Store for the Stock?

    by Zacks Equity Research

    During Athersys' (ATHX) Q4 conference call, investor focus will be on the company's progress with its investigational MultiStem cell therapy to treat various indications.

    Is a Beat in Store for Catabasis (CATB) This Earnings Season?

    by Zacks Equity Research

    Catabasis (CATB) progresses with DMD candidate, edasalonexent. However, operating expenses are likely to be lower.

    Can Segmental Growth Aid Cooper Companies' (COO) Q1 Earnings?

    by Zacks Equity Research

    Management at Cooper Companies (COO) expects solid contributions from CVI and CSI units.

    What's in Store for Vericel (VCEL) This Earnings Season?

    by Zacks Equity Research

    On Vericel's (VCEL) fourth-quarter conference call, investor focus will be on the sales figures of the company's two approved medicines -- MACI and Epicel.

    Cara (CARA) Up on IDMC's Recommendation to Continue Trial

    by Zacks Equity Research

    Cara (CARA) gains after IDMC recommended the late-stage trial on lead drug, Korsuva, to continue without any modifications.

    Cara Therapeutics (CARA) Reports Q3 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Cara (CARA) delivered earnings and revenue surprises of -10.87% and 7.34%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

    The Zacks Analyst Blog Highlights: Diageo, Constellation Brands, Cara, Cronos and GW

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: Diageo, Constellation Brands, Cara, Cronos and GW

      Sweta Killa headshot

      ETFs & Stocks to Tap Marijuana Boom

      by Sweta Killa

      Investors seeking to tap the ongoing green rush may consider these ETFs and stocks.

        Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates

        by Zacks Equity Research

        Cara (CARA) delivered earnings and revenue surprises of -4.00% and 359.84%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?